Press Releases

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2021
Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
September 22, 2021
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRAS™ (sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
September 20, 2021
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
September 19, 2021
Verastem Oncology to Present at Upcoming Investor Conferences
September 7, 2021
Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 2, 2021
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021
July 27, 2021
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt
July 19, 2021
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 6, 2021
Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors
June 24, 2021
Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference
May 25, 2021
Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
May 24, 2021
Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 11, 2021
Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022
March 18, 2021
Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference
March 2, 2021
Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology
January 20, 2021
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2021
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
January 6, 2021
Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference
January 5, 2021

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
Ajay Munshi

Investor Relations
781.469.1579
info@verastem.com

Sherri Spear

Argot Partners
617.533.0020
sherri@argotpartners.com

Investor Kit